Acuta Capital Partners, LLC Zynerba Pharmaceuticals, Inc. Transaction History
Acuta Capital Partners, LLC
- $98.8 Million
- Q3 2024
A detailed history of Acuta Capital Partners, LLC transactions in Zynerba Pharmaceuticals, Inc. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 50,000 shares of ZYNE stock, worth $0. This represents 0.09% of its overall portfolio holdings.
Number of Shares
50,000Holding current value
$0% of portfolio
0.09%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ZYNE
# of Institutions
4Shares Held
774KCall Options Held
0Put Options Held
0About Zynerba Pharmaceuticals, Inc.
- Ticker ZYNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,753,100
- Description
- Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...